Treatment strategies in elderly patients with aggressive histology lymphoma

Feasibility of collecting longitudinal patient-reported outcomes in individuals with relapsed or refractory large B-cell lymphoma who received chimeric antigen receptor T-cell (CART) therapy.

BMC cancer·2024

Comparison of Frailty Scores in Newly Diagnosed Patients with Multiple Myeloma: A Review.

The Journal of frailty & aging·2019

Impact of a novel prioritization framework on clinician-led oncology drug submissions.

Current oncology (Toronto, Ont.)·2019

Approach to evaluation of fever in ambulatory cancer patients receiving chemotherapy: A systematic review.

Cancer treatment reviews·2016

Plerixafor for autologous stem-cell mobilization and transplantation for patients in Ontario.

Current oncology (Toronto, Ont.)·2016

An open-label expanded-access trial of bendamustine in patients with rituximab-refractory indolent non-Hodgkin lymphoma or previously untreated chronic lymphocytic leukemia: BEND-ACT.

Current oncology (Toronto, Ont.)·2015

Outcomes of down syndrome-related myeloid leukemia in Turkiye: a multicenter retrospective observational cohort study by the Turkish Pediatric Hematology Association.

Annals of hematology·2026

Early deep response to cilta-cel as 2nd CAR T-Cell therapy after CELMoD-based bridging for advanced multiple myeloma.

Annals of hematology·2026

Chidamide plus venetoclax as effective and safe maintenance therapy in high-risk acute myeloid leukemia and myelodysplastic syndrome post-transplantation.

Annals of hematology·2026

Optimizing venetoclax duration with hypomethylating agents for newly diagnosed acute myeloid leukemia: impact on response and survival.

Annals of hematology·2026

Defining and managing high-risk acute myeloid leukemia (AML) in 2026.

Annals of hematology·2026

Durable CNS remission with elranatamab and intrathecal therapy in relapsed/refractory multiple myeloma.

Annals of hematology·2026

Programmed Clonal Expansion Associated with V(D)J Recombination Drives an ATM-Dependent Vulnerability Underlying Preferential Lymphocyte Depletion and Myeloid Bias Following DNA Damage.

bioRxiv : the preprint server for biology·2026

Comparative evidence on the independent contribution of granulocyte-macrophage colony-stimulating factor to anti-GD2 immunotherapy in neuroblastoma: a systematic review and gap analysis.

Frontiers in oncology·2026

Complete Resection of a Giant Middle Mediastinal Castleman Disease Using Robot-Assisted Thoracic Surgery: A Case Report.

Surgical case reports·2026

Prospective Evaluation of Thiotepa Pharmacokinetics in Children and Young Adults Undergoing Allogeneic or Autologous Hematopoietic Cell Transplantation.

Journal of clinical pharmacology·2026

Comparative Analysis of the Immune Profiles of Women and Men With Hepatocellular Carcinoma.

Cancer medicine·2026

Mucosal Melanoma: Clinical and Biological Implications of Anatomic Site.

Pigment cell & melanoma research·2026

Related Experiment Videos

Treatment strategies in elderly patients with aggressive histology lymphoma

Related Concept Videos

Feasibility of collecting longitudinal patient-reported outcomes in individuals with relapsed or refractory large B-cell lymphoma who received chimeric antigen receptor T-cell (CART) therapy.

Comparison of Frailty Scores in Newly Diagnosed Patients with Multiple Myeloma: A Review.

Impact of a novel prioritization framework on clinician-led oncology drug submissions.

Approach to evaluation of fever in ambulatory cancer patients receiving chemotherapy: A systematic review.

Plerixafor for autologous stem-cell mobilization and transplantation for patients in Ontario.

An open-label expanded-access trial of bendamustine in patients with rituximab-refractory indolent non-Hodgkin lymphoma or previously untreated chronic lymphocytic leukemia: BEND-ACT.

Outcomes of down syndrome-related myeloid leukemia in Turkiye: a multicenter retrospective observational cohort study by the Turkish Pediatric Hematology Association.

Early deep response to cilta-cel as 2nd CAR T-Cell therapy after CELMoD-based bridging for advanced multiple myeloma.

Chidamide plus venetoclax as effective and safe maintenance therapy in high-risk acute myeloid leukemia and myelodysplastic syndrome post-transplantation.

Optimizing venetoclax duration with hypomethylating agents for newly diagnosed acute myeloid leukemia: impact on response and survival.

Defining and managing high-risk acute myeloid leukemia (AML) in 2026.

Durable CNS remission with elranatamab and intrathecal therapy in relapsed/refractory multiple myeloma.

Programmed Clonal Expansion Associated with V(D)J Recombination Drives an ATM-Dependent Vulnerability Underlying Preferential Lymphocyte Depletion and Myeloid Bias Following DNA Damage.

Comparative evidence on the independent contribution of granulocyte-macrophage colony-stimulating factor to anti-GD2 immunotherapy in neuroblastoma: a systematic review and gap analysis.

Complete Resection of a Giant Middle Mediastinal Castleman Disease Using Robot-Assisted Thoracic Surgery: A Case Report.

Prospective Evaluation of Thiotepa Pharmacokinetics in Children and Young Adults Undergoing Allogeneic or Autologous Hematopoietic Cell Transplantation.

Comparative Analysis of the Immune Profiles of Women and Men With Hepatocellular Carcinoma.

Mucosal Melanoma: Clinical and Biological Implications of Anatomic Site.

Related Experiment Videos

Treatment strategies in elderly patients with aggressive histology lymphoma

Related Concept Videos

Related Articles